Based on these clinical trials, pembrolizumab as a second-line therapy has been approved by FDA for advanced ESCC patients with PD-L1 CPS ≥ 10 (Yamamoto and Kato, 2020). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.